健康照护类股ETF-SPDR(XLV)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

XLV 健康照护类股ETF-SPDR

盘后交易 05-12 16:52:52 EDT

145.85

+2.81

+1.96%

盘后145.95

+0.10+0.07%

16:51 EDT

最高146.64	最低143.19	成交量1,167万
今开143.81	昨收143.04	日振幅2.41%
总市值377.70亿	流通市值377.70亿	总股本2.59亿
成交额16.98亿	换手率4.51%	流通股本2.59亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"XLV","market":"US","secType":"STK","nameCN":"健康照护类股ETF-SPDR","latestPrice":145.85,"timestamp":1778616000000,"preClose":143.04,"halted":0,"volume":11673348,"hourTrading":{"tag":"盘后","latestPrice":145.95,"preClose":145.85,"latestTime":"16:51 EDT","volume":61163,"amount":8920414.98417,"timestamp":1778619118736,"change":0.1,"changeRate":0.000686,"amplitude":0.004023},"delay":0,"changeRate":0.01964485458612977,"floatShares":258965324,"shares":258965324,"eps":-14.217021,"marketStatus":"盘后交易","change":2.81,"latestTime":"05-12 16:52:52 EDT","open":143.805,"high":146.64,"low":143.19,"amount":1698243803.31312,"amplitude":0.024119,"askPrice":146.25,"askSize":1,"bidPrice":145.6,"bidSize":700,"shortable":3,"etf":1,"ttmEps":-14.217021,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1778630400000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":143.04,"sharesOutstanding":267365324,"nav":143.561886,"aum":36746864643.19,"dividendRate":0.016766,"bidAskSpread":0.000085,"preHourTrading":{"tag":"盘前","latestPrice":143.57,"preClose":143.04,"latestTime":"09:29 EDT","volume":13535,"amount":1941221.1012000002,"timestamp":1778592599999,"change":0.53,"changeRate":0.003705,"amplitude":0.013213},"postHourTrading":{"tag":"盘后","latestPrice":145.95,"preClose":145.85,"latestTime":"16:51 EDT","volume":61163,"amount":8920414.98417,"timestamp":1778619118736,"change":0.1,"changeRate":0.000686,"amplitude":0.004023},"volumeRatio":1.302322,"optionData":{"bulkOrders":[{"symbol":"XLV","call":false,"expireDate":1781755200000,"strike":"145.0","timestamp":1778605246092,"price":2.39,"volume":5000,"amount":1195000,"type":"+"}]},"impliedVol":0.1772,"impliedVolPercentile":0.5498},"requestUrl":"/m/hq/s/XLV","defaultTab":"news","newsList":[{"id":"2635519242","title":"Einhorn在Sohn大会力推Acadia Healthcare与Centene，强调估值错配机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2635519242","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635519242?lang=zh_cn&edition=full","pubTime":"2026-05-13 03:36","pubTimestamp":1778614560,"startTime":"0","endTime":"0","summary":"Greenlight Capital创始人David Einhorn周二在纽约Sohn投资大会上发表演讲，重点推荐Acadia Healthcare和Centene两只医疗保健股，称市场对这两家公司的负面情绪已过度反映，当前估值处于“明显错误”的水平。　　Einhorn此前已通过Greenlight Capital大幅增持Acadia，第四季度持仓增加超过150%，总持仓价值约5800万美元。　　Einhorn同时看好健康保险公司Centene。对于Acadia，催化剂在于运营效率提升和新开合资医院的逐步爬坡；对于Centene，盈利修复则来自费率的周期性回归和管理层严格的自救措施。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-13/doc-inhxsttu1093912.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LABU","XLV","BK4585","XBI","BK4588","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634403901","title":"四川金融监管局核准李正复星联合健康保险股份有限公司四川分公司副总经理任职资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2634403901","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634403901?lang=zh_cn&edition=full","pubTime":"2026-05-11 15:19","pubTimestamp":1778483947,"startTime":"0","endTime":"0","summary":"2026年05月06日，四川金融监管局核准李正复星联合健康保险股份有限公司四川分公司副总经理任职资格。公告内容如下：四川金融监管局关于李正复星联合健康保险股份有限公司四川分公司副总经理任职资格的批复川金监复〔2026〕136号复星联合健康保险股份有限公司：《复星联合健康保险股份有限公司关于李正高级管理人员任职资格许可的请示》及相关补正、说明解释材料收悉。未尽事项按金融监管总局有关规定办理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260511/32214843.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK4581","BK4588","BK4585","LABU","XLV","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634427222","title":"中信证券医疗健康2025年报及2026年一季报总结：创新板块业绩集中兑现 内外共振推动行业质变开始","url":"https://stock-news.laohu8.com/highlight/detail?id=2634427222","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634427222?lang=zh_cn&edition=full","pubTime":"2026-05-11 08:38","pubTimestamp":1778459891,"startTime":"0","endTime":"0","summary":"2025年板块收入及扣非归母净利润增速分别为+2.77%、+5.76%;2026Q1板块营业收入及扣非归母净利润增速分别为+4.74%、+5.10%。头部Pharma业务结构从传统制药向创新药转变迅速，创新药放量逐步成为营收增长的核心驱动力。2025年Pharma板块的研发费用率为13.47%，相比2024年提升4.55个百分点;2026Q1，板块的研发费用率为13.03%，相比于2025Q1提升4.11个百分点。2025年板块收入增速约27.8%，继续保持较快增长趋势。创新药出海：中国创新药全球价值不断验证，料2026年进入密集数据催化期。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439972.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1516","LU2289578879.USD","LU0405327494.USD","BK4585","BK1521","LU1255011170.USD","BK4550","BK0012","BK0028","XLV","159760","IXJ","LU2495084118.USD","VHT","600030","LU1064131003.USD","BK4588","LU1997245177.USD","BK0188","LU0405327148.USD","BK0183","LU1997245094.SGD","LU1997244956.HKD","LU1720050803.USD","LU1781817850.SGD","LU1580142542.USD","LU1328615791.USD","LU1794554557.SGD","XBI","LU1655091616.SGD","LU1064130708.USD","BK1147","06030","BK4581","BK0196","LABU","LU2148510915.USD","BK0276","BK1564"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150134395","title":"医疗保健板块动态：市场焦点解读","url":"https://stock-news.laohu8.com/highlight/detail?id=1150134395","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150134395?lang=zh_cn&edition=full","pubTime":"2026-05-08 00:26","pubTimestamp":1778171205,"startTime":"0","endTime":"0","summary":"最新医疗保健板块市场动态解读。该公司表示，在保险覆盖下，每月费用低至25美元。美东时间22:33 - 联昌国际证券分析师陈成勇在报告中表示，得益于扩建项目及患者就诊强度提升，双威医疗保健2025-2028年盈利复合年增长率预计达23.6%。分析师指出，双威医疗有望借助与母公司双威集团生态系统的深度融合获益，其城镇开发、酒店及教育资产将助力患者流量和医疗旅游业务。该股当前上涨1.6%至1.89林吉特。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4581","XLV","XBI","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633170905","title":"新股消息 | 从招股书看好医生云医疗：AI驱动的医疗健康科技平台轮廓初现","url":"https://stock-news.laohu8.com/highlight/detail?id=2633170905","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633170905?lang=zh_cn&edition=full","pubTime":"2026-05-06 13:45","pubTimestamp":1778046321,"startTime":"0","endTime":"0","summary":"不过，招股书并未单独披露AI业务收入规模。从招股书来看，好医生云医疗的平台边界，已经从早期的线上服务，延伸到多个基层医疗关键环节。从招股书可以确认，AI好医生诊疗支持系统截至2026年4月6日已覆盖：29个省235个城市520多个县区，触达8500多家基层医疗机构，服务基层医生超过2.4万人，门诊数量超过3200万人次，生成病历超过2800万份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438413.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4581","BK4550","BK4585","CHAT","VHT","AGIX","ARTY","IXJ","LABU","159891","159760","BK4588","XBI","AIPO","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160759933","title":"医疗保健板块动态聚焦：费森尤斯治疗量下滑，GSK新药进展受关注，诺和诺德口服减肥药持续领跑","url":"https://stock-news.laohu8.com/highlight/detail?id=1160759933","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160759933?lang=zh_cn&edition=full","pubTime":"2026-05-05 16:23","pubTimestamp":1777969391,"startTime":"0","endTime":"0","summary":"0744 GMT——杰富瑞分析师在研究报告中指出，费森尤斯医疗保健第一季度美国可比治疗量的下滑很可能引起投资者关注。尽管这家德国透析专业公司通过转型计划实现了成本节约，其一季度收入基本符合预期，调整后营业利润也与市场共识一致。然而分析师认为，市场焦点或将落在其医疗服务部门美国同市场治疗量0.4%的下降上。该公司股价下跌5.4%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","BK4588","BK4581","XBI","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633229968","title":"5月医疗保健股多空榜：Sensei及KalVista空头比例居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2633229968","media":"环球市场播报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633229968?lang=zh_cn&edition=full","pubTime":"2026-05-05 03:24","pubTimestamp":1777922640,"startTime":"0","endTime":"0","summary":"随着4月结束，市值20亿美元以下的小型医疗保健股空头头寸显著增加，显示市场对这类高波动性股票的看空情绪升温。　　根据最新数据，5月初医疗保健板块空头比例最高的个股包括Sensei Biotherapeutics、KalVista Pharmaceuticals和GlucoTrack。　　在空头比例较低的个股中，Beyond Air和Polaryx Therapeutics名列前茅。　　值得注意的是，表格中提及的Sensei Biotherapeutics和KalVista Pharmaceuticals均在搜索报告的5月3日数据中列为高位空头标的。投资者需警惕这类高做空比例股票可能面临的逼空风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-05/doc-inhwunrr3304552.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4550","LABU","BK4588","BK4585","XBI","BK4581","VHT","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101924243","title":"医疗保健房地产信托拟发行5亿美元可转换优先票据","url":"https://stock-news.laohu8.com/highlight/detail?id=1101924243","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101924243?lang=zh_cn&edition=full","pubTime":"2026-05-04 19:25","pubTimestamp":1777893925,"startTime":"0","endTime":"0","summary":"医疗保健房地产信托公司宣布，其运营合伙实体医疗保健房地产控股有限合伙公司计划非公开发行总本金5亿美元的2032年到期可转换优先票据。此次发行将面向符合资格的机构投资者，并受市场条件制约。资金用途方面，发行所得将分为三部分：支付上限期权交易成本、回购约7500万美元A类普通股、偿还2026年到期3.5%优先票据债务。作为全美最大的医疗门诊大楼专业运营商，医疗保健房地产信托此次融资举措引发市场关注。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4203","LU0029874061.USD","BK4137","LU0128526141.USD","XLV","BK4588","HR","BK4581","XBI","LABU","HCSG","BK4225","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139856510","title":"国家医疗房产公司宣布以5.28亿美元出售OMF资产组合","url":"https://stock-news.laohu8.com/highlight/detail?id=1139856510","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139856510?lang=zh_cn&edition=full","pubTime":"2026-05-04 18:01","pubTimestamp":1777888891,"startTime":"0","endTime":"0","summary":"纽约，2026年5月4日——国家医疗房产公司今日宣布，已就出售包含86个门诊医疗设施的资产组合达成最终买卖协议，交易金额约达5.28亿美元。若计入本次交易及约9000万美元待完成的SHOP资产收购项目，2025年第四季度SHOP板块的现金净营业收入预计将占整体投资组合现金净营业收入的60%。公司将继续以剩余OMF资产作为资本来源，支持SHOP组合的扩张战略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","NHP","OMF","BK4588","BK4585","BK4225","LABU","XBI","BK4561","BK4581","BK4166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188109821","title":"医疗保健板块动态：市场焦点对话","url":"https://stock-news.laohu8.com/highlight/detail?id=1188109821","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188109821?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:23","pubTimestamp":1777537402,"startTime":"0","endTime":"0","summary":"1039 GMT - 葛兰素史克首席执行官卢克·米尔斯表示，这家英国制药巨头未来的交易或将延续其近期斥资22亿美元收购过敏药物开发商RAPT Therapeutics的模式。米尔斯补充道，由于拓展新领域的壁垒较高，葛兰素史克在未来的并购中更倾向于聚焦已有商业布局的领域或相邻赛道。该集团于今年1月米尔斯接任CEO数周后敲定对RAPT的收购，并于3月完成交易。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","XLV","XBI","LABU","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143202254","title":"医疗保健行业动态聚焦：市场热点解析","url":"https://stock-news.laohu8.com/highlight/detail?id=1143202254","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143202254?lang=zh_cn&edition=full","pubTime":"2026-04-28 00:23","pubTimestamp":1777306981,"startTime":"0","endTime":"0","summary":"两家公司在抗癌药物Enhertu和Datroway方面是合作伙伴。第一三共上周以审查其肿瘤产品组合和研发管线的供应计划为由，推迟了2026财年业绩的发布。分析师认为，此举可能与第一三共解决其生产网络问题的努力有关。他们补充道，预计这对Enhertu和Datroway等抗癌药物的销售影响甚微或没有影响，因此对阿斯利康不会产生实质性影响。阿斯利康股价上涨0.3%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4585","LABU","UBS","XLV","BK4581","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158727907","title":"医疗保健行业动态聚焦：市场观点速递","url":"https://stock-news.laohu8.com/highlight/detail?id=1158727907","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158727907?lang=zh_cn&edition=full","pubTime":"2026-04-25 00:22","pubTimestamp":1777047769,"startTime":"0","endTime":"0","summary":"生物梅里埃稳健的资产负债表与净现金头寸为这家制药企业提供了并购机遇。在检测领域，该法国药企仍被列为首选标的，其竞争对手凯杰与索灵或因呼吸道疾病季温和及中东冲突影响而承压。股价当前下跌2.7%至71.30欧元，年内累计跌幅达35%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4581","XBI","LABU","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629890197","title":"前高盛合伙人李逸斌出任摩根大通(JPM.US)全球医疗保健投行业务联席主管","url":"https://stock-news.laohu8.com/highlight/detail?id=2629890197","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629890197?lang=zh_cn&edition=full","pubTime":"2026-04-24 14:45","pubTimestamp":1777013116,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据媒体报道，摩根大通 任命Jerry Lee李逸斌、Nick Richitt为全球医疗保健投资银行联席主管。Jerry Lee，刚于今年第一季度加入摩根大通，此前他在高盛工作逾19年，他于2020年便晋升为高盛合伙人，离开高盛前担任全球生物医药投行业务和医疗保健投行业务主管，职业生涯中已为逾3000亿美元的已宣布并购交易提供过咨询。Jerry Lee，1999年获耶鲁大学学士学位、2007年获宾夕法尼亚大学沃顿商学院MBA学位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1433281.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2746668461.USD","LU1064131342.USD","LU2237443622.USD","LU1868836914.USD","LU2054465674.USD","IE00BDRTCR15.USD","XBI","LU2023250504.SGD","LU0345769631.USD","LU0345770993.USD","LU0256863811.USD","LU0203345920.USD","LU0265550359.USD","LU1366192091.USD","BK4127","IE00BN8TJ469.HKD","LU1145028129.USD","XLV","BK4207","LU1720051017.SGD","LU2237438978.USD","LU2592432038.USD","LU0203347892.USD","LU1267930490.SGD","LU0976567544.SGD","LU1548497426.USD","BK4533","GSX","IE00BDCRKT87.USD","LU1868836757.USD","LU1917777945.USD","LU2237443549.SGD","LU0061475181.USD","LU1551013425.SGD","LU2552382132.HKD","BK4534","LU2750360997.AUD","LU0640476718.USD","LU1363072403.SGD","JPMO","JPO","IE0034235295.USD","LU0310799852.SGD","VHT","LABU","BK4504","LU0215105999.USD","LU0859254822.USD","LU2756315318.SGD","LU2430703178.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158690158","title":"医疗保健板块动态聚焦：罗氏业绩符合预期，科利耳前景承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1158690158","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158690158?lang=zh_cn&edition=full","pubTime":"2026-04-23 16:24","pubTimestamp":1776932649,"startTime":"0","endTime":"0","summary":"0810 GMT - 杰富瑞分析师指出，罗氏第一季度销售额基本符合市场预期。这家瑞士制药巨头将于周四晚些时间举行电话会议，预计将重点讨论其长期销售前景。分析师补充称，市场将密切关注罗氏对多发性硬化症药物芬努替尼的信心表现，同时其乳腺癌药物Giredestrant的商业化机遇也引发投资者兴趣。罗氏股价当前上涨2.3%至320.4瑞士法郎。流行病防范创新联盟已承诺提供最高5430万美元支持疫苗研发。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4585","XLV","BK4588","XBI","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629076948","title":"探索健康保险发展新路径","url":"https://stock-news.laohu8.com/highlight/detail?id=2629076948","media":"经济日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629076948?lang=zh_cn&edition=full","pubTime":"2026-04-23 06:00","pubTimestamp":1776895205,"startTime":"0","endTime":"0","summary":"近日，第一届海南自贸港博鳌乐城健康保险高质量发展大会举行。来自监管部门、保险行业、高校和医疗机构的代表齐聚一堂，围绕加快发展健康保险，推动健康保险与医疗健康产业深度融合创新等话题展开讨论，共同探讨健康保险高质量发展新路径。健康保险主要包括商业医疗保险、商业长期护理保险、失能收入损失保险和疾病保险四大类险种。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604233714848012.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["XLV","BK4581","BK4588","BK4585","LABU","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629209736","title":"美股医疗 REITs 融资遇冷：National Healthcare(NHP.US)折价完成 IPO，最终募资4.62亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629209736","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629209736?lang=zh_cn&edition=full","pubTime":"2026-04-22 14:35","pubTimestamp":1776839700,"startTime":"0","endTime":"0","summary":"智通财经APP注意到，房地产投资信托基金National Healthcare Properties Inc.的 IPO 定价低于其原定区间，最终筹集了4.62亿美元。声明显示，National Healthcare计划将募集资金用于多种用途，包括偿还其循环信贷额度中约1.86亿美元的借款，以及为未来的物业收购提供资金。根据招股文件，National Healthcare在2025年营收为3.423亿美元，净亏损为5770万美元；而上年同期营收为3.54亿美元，净亏损为1.903亿美元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431811.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LABU","BK4581","SPCX","XLV","NHP","CFA","159891","BK4588","IPOS","XBI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629930310","title":"葛兰旗下中欧医疗健康混合一季报：药明康德(603259.SH)位列第一大重仓股 二季度看好创新产业链","url":"https://stock-news.laohu8.com/highlight/detail?id=2629930310","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629930310?lang=zh_cn&edition=full","pubTime":"2026-04-22 10:52","pubTimestamp":1776826345,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月22日，中欧基金披露葛兰和赵磊共同管理的中欧医疗健康混合型证券投资基金2026年第1季度报告。葛兰表示，一季度基于长期价值投资思路，继续重点关注创新药械及其产业链、消费医疗等领域。调仓换股方面，与2025年第4季度相比，中欧医疗健康混合在一季度减仓了康龙化成、泰格医药等个股，增持了凯莱英、信立泰、海思科、科伦药业，而艾力斯新进持仓前十。创新药及产业链预计将延续高景气度，是二季度重点关注方向。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431729.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IXJ","BK0216","LU2488822045.USD","02359","LU0456842615.SGD","LU0320764599.SGD","BK1141","XLV","BK1576","VHT","603259","LU1979443071.USD","BK4588","LU1997244956.HKD","LU1997245094.SGD","LU2495084118.USD","LU2328871848.SGD","LU0052750758.USD","XBI","LU1046422090.SGD","LU1934453819.USD","BK4581","LU2045819591.USD","LU0348766576.USD","BK4550","159760","LU2125910500.SGD","LU1808992512.USD","LU1969619763.USD","LU0708995583.HKD","LU1997245177.USD","LU0348767384.USD","LU2242644610.SGD","BK1583","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629080017","title":"美国健康保险公司股价盘前上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2629080017","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629080017?lang=zh_cn&edition=full","pubTime":"2026-04-21 18:29","pubTimestamp":1776767357,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月21日，美国健康保险公司股价盘前上涨，此前联合健康第一季度利润超出预期。CVS健康上涨3.3%，Elevance上涨3.2%，Cigna上涨1.3%，Humana上涨2.9%，MolinaHealthcare上涨3%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604213712493616.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"059177759f9d48b3b3bd76393f707d29","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604213712493616.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["XLV","BK4585","BK4588","LABU","BK4581","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628622524","title":"顶级阵容齐聚！乐城这场大会共探健康保险未来新生态，最新议程→","url":"https://stock-news.laohu8.com/highlight/detail?id=2628622524","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628622524?lang=zh_cn&edition=full","pubTime":"2026-04-17 09:41","pubTimestamp":1776390060,"startTime":"0","endTime":"0","summary":"　　4月16日-18日，第一届海南自贸港博鳌乐城健康保险高质量发展大会暨第三届多层次健康保障研讨会将在博鳌亚洲论坛东屿岛大酒店举办。推动商业健康保险向质量效益、创新驱动转型，已成为完善中国特色多层次医疗保障体系、服务民生福祉的时代任务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/insurance/bxdt/2026-04-17/doc-inhuuimk6607344.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["XLV","LABU","XBI","BK4588","BK4585","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628240719","title":"中信证券：药价形成机制迎来大调整 医疗健康产业政策改革进入密集期","url":"https://stock-news.laohu8.com/highlight/detail?id=2628240719","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628240719?lang=zh_cn&edition=full","pubTime":"2026-04-17 08:12","pubTimestamp":1776384738,"startTime":"0","endTime":"0","summary":"医疗健康产业政策改革进入密集期，建议持续关注政策驱动下的医疗健康产业投资机会。中信证券主要观点如下：事件：4月14日，国务院办公厅印发《关于健全药品价格形成机制的若干意见》，15日国务院政策例行吹风会介绍健全全周期全渠道药品价格形成机制有关情况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429712.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1521","LU1064131003.USD","BK0012","LU1794554557.SGD","LU1720050803.USD","LU1580142542.USD","BK1564","BK4588","BK1147","LU1064130708.USD","LU2148510915.USD","BK1516","XLV","XBI","LABU","LU0405327148.USD","BK0188","BK0196","LU1655091616.SGD","159760","IXJ","LU1997245177.USD","LU2289578879.USD","BK4581","LU1255011170.USD","BK0276","LU1328615791.USD","BK0028","BK4550","LU1997245094.SGD","LU1997244956.HKD","BK0183","VHT","LU1781817850.SGD","LU0405327494.USD","BK4585","600030","LU2495084118.USD","06030"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://us.spdrs.com/etf/health-care-select-sector-spdr-fund-XLV","stockEarnings":[{"period":"1week","weight":-0.0117},{"period":"1month","weight":-0.029},{"period":"3month","weight":-0.0791},{"period":"6month","weight":-0.064},{"period":"1year","weight":0.0781},{"period":"ytd","weight":-0.076}],"compareEarnings":[{"period":"1week","weight":0.0297},{"period":"1month","weight":0.0881},{"period":"3month","weight":0.0682},{"period":"6month","weight":0.0818},{"period":"1year","weight":0.31},{"period":"ytd","weight":0.0841}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"本基金追踪标普健康板块指数(S&P Health Care Select Sector index)，并将95%以上的资产投资在该指数包含的成分股，其中包含了医疗保健、生物科技、制药相关的公司。\n风险提示：标的成分和权重，有可能随着时间的迁移而发生变化。","yearOnYearQuotes":[{"month":1,"riseRate":0.607143,"avgChangeRate":0.009527},{"month":2,"riseRate":0.571429,"avgChangeRate":-0.002019},{"month":3,"riseRate":0.571429,"avgChangeRate":0.0058},{"month":4,"riseRate":0.535714,"avgChangeRate":0.012982},{"month":5,"riseRate":0.642857,"avgChangeRate":0.003595},{"month":6,"riseRate":0.518519,"avgChangeRate":0.002804},{"month":7,"riseRate":0.62963,"avgChangeRate":0.011509},{"month":8,"riseRate":0.555556,"avgChangeRate":0.001611},{"month":9,"riseRate":0.37037,"avgChangeRate":-0.015959},{"month":10,"riseRate":0.592593,"avgChangeRate":0.007405},{"month":11,"riseRate":0.777778,"avgChangeRate":0.02456},{"month":12,"riseRate":0.666667,"avgChangeRate":0.010581}],"exchange":"ARCA","name":"健康照护类股ETF-SPDR","nameEN":"Health Care Select Sector SPDR Fund"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"健康照护类股ETF-SPDR(XLV)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供健康照护类股ETF-SPDR(XLV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"健康照护类股ETF-SPDR,XLV,健康照护类股ETF-SPDR股票,健康照护类股ETF-SPDR股票老虎,健康照护类股ETF-SPDR股票老虎国际,健康照护类股ETF-SPDR行情,健康照护类股ETF-SPDR股票行情,健康照护类股ETF-SPDR股价,健康照护类股ETF-SPDR股市,健康照护类股ETF-SPDR股票价格,健康照护类股ETF-SPDR股票交易,健康照护类股ETF-SPDR股票购买,健康照护类股ETF-SPDR股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"健康照护类股ETF-SPDR(XLV)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供健康照护类股ETF-SPDR(XLV)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}